Form 4: Sensei Biotherapeutics Director William R. Ringo Acquires 19,000 Stock Options

Director William R. Ringo acquired 19,000 stock options in Sensei Biotherapeutics, Inc. on June 11, 2024, at an exercise price of $0.709.

Summary

• On June 11, 2024, William R. Ringo, a director of Sensei Biotherapeutics, Inc., acquired 19,000 stock options.
• The exercise price for these options is $0.709.
• The options vest in 12 equal monthly installments over one year, becoming fully vested on June 11, 2025, contingent upon continuous service with the Issuer.
• The options will be fully vested on the date of the Company's next annual stockholder meeting, subject to continuous service with the Issuer through such vesting date.
• Following the transaction, Ringo directly owns 19,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option acquisition by a director, indicating alignment with company performance but not necessarily a strong positive or negative signal.

Positives

• The acquisition of stock options by a director signals confidence in the company's future prospects.

Future Outlook

The vesting schedule indicates a commitment from the director to remain with the company for at least one year.

Industry Context

Form 4 filings are standard disclosures for insiders, providing transparency into their transactions and holdings in the company.

Stakeholder Impact

• The acquisition of stock options by a director can be viewed positively by shareholders as it aligns the director's interests with the company's performance.

Key Dates

Keywords

stock options, Sensei Biotherapeutics, Form 4, director, SNSE, acquisition, vesting